J Robot Surg. 2025 Aug 31;19(1):537. doi: 10.1007/s11701-025-02641-6.
ABSTRACT
To assess how morbid obesity influences perioperative and oncological outcomes following robot-assisted radical prostatectomy (RARP). A comprehensive literature search was conducted across PubMed, Web of Science, Scopus, and Google Scholar, covering publications up to June 2025. Eligible studies included those that compared outcomes between patients with morbid obesity (defined as BMI ≥ 40 kg/m2) and those without. Data extraction and synthesis were performed using Review Manager 5.3. For meta-analysis, a random-effects model was applied, with categorical variables evaluated through odds ratios (ORs) and continuous outcomes assessed using weighted mean differences (WMDs). Three propensity score-matched studies involving 534 patients were included. Individuals with morbid obesity showed increased intraoperative blood loss (MD: 37.62 mL; 95% CI: 13.16-62.09; p = 0.003) and a higher incidence of postoperative overall complications (OR: 1.58; 95% CI: 1.04-2.41; p = 0.03). Operative and console durations were generally longer, though results varied. No marked differences were found in hospital stay or catheterization period. Oncologically, patients with morbid obesity exhibited more advanced pathological staging and higher rates of positive surgical margins. In contrast, nerve-sparing rates and lymph node dissection frequencies were comparable between groups. Although RARP can be safely performed in patients with morbid obesity, it presents added technical complexity and may be linked to less favorable pathological outcomes. Individualized perioperative planning and further prospective trials are essential to improve care for this patient group.
PMID:40886236 | DOI:10.1007/s11701-025-02641-6
